Figure 2.

Average proportion of patients with (A) chronic lymphocytic leukemia, (B) multiple myeloma, (C) non‐Hodgkin lymphoma, and (D) other lymphoproliferative diseases, treated with Ig, with or without antibiotics in parallel over the last 12 mo. The dashed line indicates the average of patients treated with Ig, with or without antibiotics in parallel across all countries (CLL [32%], MM [33%], NHL [25%], and other lymphoproliferative diseases [26%]). Patients referred for Ig treatment are excluded, as for these patients no information on antibiotic usage was available. The values for average proportion of patients treated with Ig differed marginally when including referred patients